A biotech incubated by RA Capital has secured a $57.5 million Series B to begin a mid-stage trial for its cardio drug this ...

The company also announced the appointment of its current Executive Chair, Alvin Shih, MD to the Chief Executive Officer role, plus the appointment of Rebecca Luse, Managing Director at Deep Track ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

Needham analyst Serge Belanger maintained a Buy rating on Cytokinetics ( CYTK – Research Report) today and set a price target of $72.00. The company’s shares closed yesterday at $35.99. Filter, ...

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – ...

Cytokinetics, Incorporated’s CYTK share price has surged by 13.20%, which has investors questioning if this is right time to ...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its ...

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ: CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...

Cytokinetics (CYTK) stock rises and rival Edgewise (EWTX) stock drops as the latter posts mixed Phase 2 trial data for its ...

Vanguard Group Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.3% in the ...

In a regulatory filing, Cytokinetics (CYTK) president and CEO Robert Blum disclosed the sale of 15,000 common shares of the company on March 31 ...